Technical guide

What is liposomal technology? From ingredient to formulation

Liposomal technology is a formulation approach that combines a selected active ingredient with carrier structures made from phospholipids. Choosing an ingredient requires consideration of its identity and active content, the carrier system and the intended finished format. This guide explains which questions a liposomal ingredient dossier should answer before development begins.

How does a liposome work?

Liposomes are small vesicles with an aqueous compartment enclosed by one or more lipid bilayers. The water-interacting heads and lipid-interacting tails of phospholipids contribute to this arrangement. Depending on its properties, an active ingredient may be associated with the aqueous region or the lipid bilayer.

The structure is a formulation tool that can change how an ingredient behaves. The outcome depends on lipid composition, active properties, manufacturing conditions and the environment in the finished product.

Source: FDA (2018) — Liposome Drug Products; technical characterisation reference; Romano et al. (2024) — Liposomal vitamin C formulation research

Three questions require different evidence

Separating structure, composition and performance makes a technical dossier easier to assess. A single analytical method cannot answer all three questions.

QuestionEvidence to examineDevelopment purpose
What is the carrier structure?Microscopy, particle size and size distributionCharacterisation of the liposomal system
How much active is present?Identity, assay and batch-specific CoAIngredient and serving calculations
What was observed in research?Formulation-specific absorption or clinical studyRelevance of findings to the target product

Source: FDA (2018) — Liposome Drug Products; technical characterisation reference; NCI — Nanotechnology Characterization Laboratory methods

Keep research linked to the tested formulation

A published 2024 vitamin C trial in 27 participants compared a particular liposomal formulation with an equal active amount of standard vitamin C and placebo. A study of this kind describes the tested formulation under its study conditions. Applying its findings to another supplier’s formulation requires a separate justification.

Review the study identity, ingredient composition, administered active amount and observation period together. The word “liposomal” alone does not define a particular absorption ratio or clinical outcome.

Source: Purpura et al. (2024) — Formulation-specific human vitamin C trial

Information that helps start your project

At Biontera, the first assessment starts with your intended product. Capsules, sachets and liquid formats place different demands on an ingredient, so the material specification is reviewed alongside the manufacturing plan.

  • The active ingredient and target amount per serving.
  • Finished format, other ingredients and planned processing steps.
  • Intended shelf life, packaging and storage conditions.
  • Required technical documents, sample quantity and estimated annual demand.

Common questions

Do “liposomal” and “lipozomal” describe different technologies?

They are different spellings used in Turkish for the same liposome-based approach. Composition and characterisation evidence matter more than the spelling.

Are all liposomal ingredients the same size?

No. Size and size distribution depend on the formulation and measurement conditions. A product-specific report is needed.

Is liposomal technology suitable for every active?

Suitability depends on the active and intended dosage format. Sample evaluation and formulation work help establish the appropriate approach.

Explore the portfolio

From understanding to selection.

Let’s assess your next formulation.

Share your dosage form, intended amount per serving and estimated annual requirement. We can plan ingredient selection, technical documentation and sample evaluation together.

Discuss documents and samples